Q2 2026 Cellebrite DI Ltd Earnings Call Transcript
Key Points
- Cellebrite DI Ltd (CLBT) reported a 21% increase in ARR to $508 million, with strong growth in the Defense and Intelligence segment at 25%.
- The company saw significant adoption of new products like Guardian Investigate, Advanced Unlocks, and Drone Forensics, which contributed to ARR growth in their first full quarter.
- Genesis, launched in June, secured over half a dozen customers and $400,000 in ARR within weeks, with strong early product-market fit and expansion into international markets.
- US Federal business reaccelerated with mid-teens growth, and the company secured its first major FedRAMP deal for Guardian, a multimillion-dollar multiproduct order.
- The company raised its full-year adjusted EBITDA target to $153-$159 million, reflecting disciplined cost management and improved profitability despite revenue headwinds.
- Cellebrite DI Ltd (CLBT) missed its Q2 ARR and revenue guidance due to delays in large transactions, particularly in US federal and European government sectors.
- The company lowered its full-year ARR guidance to $550-$560 million and revenue to $555-$561 million, citing elongated sales cycles and procurement complexities.
- Insights conversions are yielding lower-than-expected ARR uplift, especially in the US state and local government sector, impacting growth.
- The company faced unexpected administrative and procurement requirements due to its foreign entity status, causing delays and uncertainty in deal closures.
- FX headwinds from the Israeli Shekel are negatively impacting profitability, with the company absorbing nearly 3 points of FX headwinds in its outlook.
Welcome to the Cellebrite second-quarter 2026 financial results conference Call. (Operator Instructions)
I would now like to turn the call over to your first speaker today, Mr. Andrew Kramer. Mr. Kramer, the floor is yours.
Thank you very much, operator, and good morning, everybody. Welcome to Cellebrite's second-quarter 2026 financial results call. I'm joined this morning by our primary speakers, Adam Clammer, Cellebrite's Chairman of the Board. Shiven Ramji, Cellebrite's new CEO; and David Barter, Cellebrite's CFO. Shiv, Dave and Marcus Jewell, our CRO, will participate in our Q&A session. This call is being recorded, and a replay of the recording will be made available on our website shortly after the call along with a copy of the transcript.
Please note that today's press release and financial statements, including GAAP to non-GAAP reconciliations are available on the Investor Relations website at investors.cellebrite.com. In addition to the press release, we posted
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
